Early studies have shown that combining the MEK inhibitor trametinib with the CDK4/6 inhibitor palbociclib (T/P) enhances anti-tumor effects by inducing tumor cell senescence through Rb and activating NK cells [146]. Here, CDK4 is linked to neoplasm.